# Evaluation of UCPVax Vaccine +/- Pembrolizumab Combined With Standard Treatment as Adjuvant Therapy in Patients With Unmethylated MGMT Glioblastoma

> **NCT07347210** · PHASE2 · NOT_YET_RECRUITING · sponsor: **Centre Hospitalier Universitaire de Besancon** · enrollment: 98 (estimated)

## Conditions studied

- Primary Glioblastoma

## Interventions

- **DRUG:** UCPVax
- **DRUG:** Pembrolizumab
- **DRUG:** Temozolomide

## Key facts

- **NCT ID:** NCT07347210
- **Lead sponsor:** Centre Hospitalier Universitaire de Besancon
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** NOT_YET_RECRUITING
- **Start date:** 2026-01
- **Primary completion:** 2029-01
- **Final completion:** 2029-07
- **Target enrollment:** 98 (ESTIMATED)
- **Last updated:** 2026-01-16

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07347210

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07347210, "Evaluation of UCPVax Vaccine +/- Pembrolizumab Combined With Standard Treatment as Adjuvant Therapy in Patients With Unmethylated MGMT Glioblastoma". Retrieved via AI Analytics 2026-06-23 from https://api.ai-analytics.org/clinical/NCT07347210. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*